Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13619190 | 0.89 | KMT2A (0.39) | TP53POLBMAPTMEN1KMT2A | |
| SCHEMBL4254351 | 0.89 | CASP3 (0.40) | PTGDR2CYP19A1TP53POLB | |
| SCHEMBL13619963 | 0.88 | NPBWR1 (0.42) | TP53POLBMAPTMEN1KMT2A | |
| SCHEMBL8221577 | 0.83 | TP53 (0.38) | PTGDR2CYP19A1TP53POLBMAPT | |
| SCHEMBL4256524 | 0.83 | CTSB (0.37) | PTGDR2CYP19A1TP53POLBMAPT | |
| SCHEMBL13619431 | 0.81 | POLB (0.40) | TP53POLBMAPTMEN1KMT2A | |
| SCHEMBL13608161 | 0.79 | ALDH1A1 (0.41) | IDO1TDO2SMN1; SMN2 | |
| SCHEMBL4254506 | 0.79 | ALDH1A1 (0.41) | IDO1TDO2SMN1; SMN2 | |
| SCHEMBL4255723 | 0.78 | CASP3 (0.42) | TP53POLBMAPTKMT2ASMN1; SMN2 | |
| SCHEMBL13619354 | 0.78 | OPRL1 (0.33) | TP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291959-A1 | CASPASE INHIBITORS BASED OF PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291959-A1 | CASPASE INHIBITORS BASED OF PYRIDAZINONE SCAFFOLD | CASP1, CASP2, CASP5 | PTGDR2 4130/4885CYP19A1 2416/4885PTGES 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.